Clinical Trials Cultivation DEA THC 
The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
Cannabis Law Report
NOVEMBER 4, 2021
Drug Enforcement Agency (DEA) to cultivate marijuana for research purposes. The DEA dragged their feet on this plan for years, so lawsuits were filed. delta-9 THC, meaning they aren’t a controlled substance under federal law. Use the plants for their own studies and/or FDA clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
APRIL 11, 2022
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”.
CannaMD
AUGUST 8, 2020
But CBD’s stolen the spotlight, partially because of its good cop/bad cop relationship with another famous cannabinoid: T etrahydrocannabinol or THC. THC is responsible for marijuana’s psychoactive effects. If you feel “high,” THC’s usually to blame. This new bill allows broad hemp cultivation.
Cannabis Law Report
JUNE 4, 2021
With Delta 8, one is not going to have an anxious or paranoia episode as can be common for newcomers to marijuana forms of cannabis – especially with high concentration of THC that is readily available today. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.
SpeedWeed
MARCH 5, 2021
One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.
Cannabis Law Report
APRIL 1, 2019
Selling dried cannabis to pharmaceutical companies as well as Cannabidiol (CBD) and Tetrahydrocannabinol (THC) extracts as soon as it is licensed, is the intention of Thailand’s tobacco authority among new measures to turn a profit on its dwindling cigarette business. Watch Out for May-June Regulations.
Expert insights. Personalized for you.
133 
Let's personalize your content